Nohara Y, Hanai T, Suzuki J, Matsumoto G, Iinuma F, Kubo H, Kinoshita T, Watanabe M
Faculty of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan.
Biol Pharm Bull. 2000 Sep;23(9):1015-20. doi: 10.1248/bpb.23.1015.
An automated system for HPLC-fluorometry of serum guanidino compounds was constructed. This system accomplished simultaneous removal of protein and uremic fluorescences, abundant in the sera of uremic patients, which interfere with the fluorometric assay. This system was applied to the detailed elucidation of the behavior of guanidinosuccinic acid and methylguanidine during and after hemodialysis therapy (HD). The uremic patients who are capable of excreting urine even under hemodialysis therapy showed low serum guanidinosuccinic acid and methylguanidine levels. The prolongation of the interval between HD for one of the patients capable of excreting urine was examined. The levels of guanidinosuccinic acid and methylguanidine did not significantly increase and no hazardous effect was observed by 2 d of prolongation.
构建了一种用于血清胍类化合物高效液相色谱-荧光测定法的自动化系统。该系统能同时去除蛋白质和尿毒症荧光，尿毒症患者血清中富含这些物质，会干扰荧光测定。该系统被用于详细阐明血液透析治疗（HD）期间及之后胍基琥珀酸和甲基胍的行为。即使在血液透析治疗期间仍能排尿的尿毒症患者血清胍基琥珀酸和甲基胍水平较低。对其中一名能排尿的患者延长血液透析间隔时间进行了研究。延长2天，胍基琥珀酸和甲基胍水平未显著升高，也未观察到有害影响。
